Work

Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Year: 2017

Type: article

Study design: Clinical Trial

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2017.03.237

Authors: Shaji Kumar, Norbert Grzasko, Sossana Delimpasi, Wieslaw Jędrzejczak, Sebastian Grosicki, Marie Christine Kyrtsonis, Andrew Spencer, Neeraj Gupta, Zhaoyang Teng, Catriona Byrne, Richard Labotka, Meletios Athanasios Dimopoulos

Institutions: Mayo Clinic, Medical University of Lublin, Evangelismos Hospital, Medical University of Warsaw, Medical University of Silesia, National and Kapodistrian University of Athens, The Alfred Hospital, Monash University, Takeda Oncology (United States)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2606074403

FWCI: 1.792

Cites:

Cited by: 10

Related to: 10